

 EPICS An abstract graphic on the left side of the slide consists of several thick, curved lines in various colors (teal, green, orange, grey, light blue) arranged in a circular pattern, resembling a stylized sunburst or a cluster of cells.

CAR T and Bispecific Agents in Hematologic Malignancies

September 7 and 15, 2021

Content	Slide
Meeting Snapshot	3 →
Faculty Panel	4 →
Meeting Agenda	5 →
Strategic recommendations	7 →
Global perspectives	
• Summary of faculty presentation	24 →
• Key takeaways	

EPICS

VIRTUAL CLOSED-DOOR ROUNDTABLE



DATE:
September 7 and
15, 2021



**DISEASE STATE AND
DATA PRESENTATIONS**
by key experts



INSIGHTS REPORT
including postmeeting
analyses and actionable
recommendations




PANEL: 9 Key US
experts in lymphoma,
leukemia, and
myeloma



**DISEASE-SPECIFIC
DISCUSSIONS** on
therapeutic advances and
their application in clinical
decision-making

Panel Consisting of 9 US Hematology Experts



Meeting Agenda – Day 1

Time (CDT)	Topic	Speaker/Moderator
4.00 PM – 4.10 PM	Welcome, Introductions, and Meeting Objectives	Elias Jabbour, MD
4.10 PM – 4.25 PM	CAR T Cells in DLBCL	Sattva Neelapu, MD
4.25 PM – 4.50 PM	Discussion	
4.50 PM – 5.05 PM	CAR T Cells in MCL and FL	Krishna Komanduri, MD
5.05 PM – 5.30 PM	Discussion	
5.30 PM – 5.35 PM	Break	
5.35 PM – 5.50 PM	Bispecific Agents in B-NHL	Julio Chavez, MD
5.50 PM – 6.15 PM	Discussion	
6.15 PM – 6.30 PM	Managing Toxicity of Bispecific Agents and CAR T Cells	Krina Patel, MD
6.30 PM – 6.55 PM	Discussion	
6.55 PM – 7.00 PM	Wrap-up and Overview of Day 2 Activities	Elias Jabbour, MD

Meeting Agenda – Day 2

Time (CDT)	Topic	Speaker/Moderator
4.00 PM – 4.10 PM	Welcome, Introductions, and Meeting Objectives	Elias Jabbour, MD
4.10 PM – 4.25 PM	CAR T Cells in Leukemias (including ALL/AML)	Jae Park, MD
4.25 PM – 4.50 PM	Discussion	
4.50 PM – 5.05 PM	Bispecific Agents in Leukemias	Ibrahim Aldoss, MD
5.05 PM – 5.30 PM	Discussion	
5.30 PM – 5.35 PM	Break	
5.35 PM – 5.50 PM	CAR T Cells in MM	Noopur Raje, MD
5.50 PM – 6.15 PM	Discussion	
6.15 PM – 6.30 PM	Bispecific Agents in Myeloma	Sagar Lonial, MD
6.30 PM – 6.55 PM	Discussion	
6.55 PM – 7.00 PM	Conclusions and Wrap-up	Elias Jabbour, MD

EPICS

Updates in CAR T Cells and Bispecific Agents



CAR T Cells in DLBCL (1/2)

Presented by Sattva Neelapu, MD

NEW STANDARD OF CARE FOR RELAPSED/REFRACTORY DLBCL

> There are currently 3 approved CAR T-cell

Choosing CAR T product in real world setting:

(Blurred content area containing text and possibly a chart or diagram related to CAR T cell selection.)





CAR T Cells in DLBCL (2/2)

Presented by Sattva Neelapu, MD

RESEARCH AND FUTURE DIRECTIONS

> CAR T cells are being investigated in earlier lines of therapy,

[Blurred text area containing research details]





CAR T Cells in MCL and FL (1/2)

Presented by Krishna Komanduri, MD

CAR T CELLS BECOMING ESTABLISHED IN OTHER NHL SUBTYPES

> In July 2020, brexucabtagene autoleucel

ZUMA-2: Updated Results

[Blurred text area containing details about the ZUMA-2 trial results]





CAR T Cells in MCL and FL (2/2)

Presented by Krishna Komanduri, MD

> The ZUMA-5 trial resulted in approval of axi-cel in patients with

[Blurred text area containing details of the ZUMA-5 trial results and approval of axi-cel]





Bispecific Agents in B-NHL (1/2)

Presented by Julio Chavez, MD, MS

> While CAR-engineered cellular therapy

Bispecific Antibodies in B-NHL: Efficacy

Blended slide content, likely containing a table or chart comparing efficacy metrics (e.g., ORR, CR, CRi) for various bispecific antibody regimens in B-NHL. The text is blurred but appears to list different treatment groups and their corresponding clinical outcomes.





Bispecific Agents in B-NHL (2/2)

Presented by Julio Chavez, MD, MS

> Other bispecific agents, such as AFM13, target CD30-positive

[Blurred text area containing additional information about bispecific agents and CD30-positive targets.]





Managing Toxicity of Bispecific Agents and CAR T Cells

Presented by Krina Patel, MD

> An overview of toxicity with CAR T cells and bispecific agents

> The experience with bispecific agents has generally been

[Blurred text area]






CAR T Cells in Leukemias (1/2)

Presented by Jae Park, MD

CAR T CELLS FOR PEDIATRIC AND ADULT PATIENTS WITH ALL

> In leukemias, the development of CAR T

Covariates	Responding Patients/ Evaluable Patients	Percent of Patients With Response (95% CI)





CAR T Cells in Leukemias (2/2)

Presented by Jae Park, MD

> Areas of investigation for CAR T cells in ALL include improving

> The development of CAR T cells in AML has faced challenges

[Blurred text area]





Bispecific Agents in Leukemias (1/2)

Presented by Ibrahim Aldoss, MD

RESEARCH AND FUTURE DIRECTIONS

> The majority of clinical data with bispecific

Key takeaways

[Blurred text area containing key takeaways]





Bispecific Agents in Leukemias (2/2)

Presented by Ibrahim Aldoss, MD

> In the ongoing E1910 study, patients who are MRD-negative

[Blurred text area]





CAR T Cells in MM (1/2)

Presented by Noopur Raje, MD

RECENT APPROVALS AND PATHS TO OPTIMIZATION

> CAR T cells are part of the standard of care

Targeting BCMA may be a new standard





CAR T Cells in MM (2/2)

Presented by Noopur Raje, MD

> In contrast to the PFS plateau seen with CAR T-cell therapy in





Bispecific Agents in Myeloma

Presented by Sagar Lonial, MD

> Multiple bispecific agents are in development in MM

[Blurred text area containing additional information or a list of agents]



EPICS

Key Insights

CAR T Cells in DLBCL (1/2)

Given that there are currently 3 approved chimeric antigen receptor (CAR) T-cell therapies (axi-cel, tisa-cel, and liso-cel) for patients with

[Blurred content area]





[Blurred content area]

CAR T Cells in DLBCL (2/2)

The experts think moving CAR T cells into the frontline setting will be

Regarding the feasibility of administering CAR T-cell therapy in the



CAR T Cells in MCL and FL

While the experts would generally prefer to give a Bruton tyrosine kinase (BTK) inhibitor before CAR T-cell therapy in patients with

[Blurred text area]



[Blurred text area]

Bispecific Agents in B-NHL

In terms of how bispecific agents compare with CAR T cells, expert opinion is that response rates are similar; however, the follow-up time with

[Blurred content area]



[Blurred content area]

Managing Toxicity of Bispecific Agents and CAR T Cells (1/2)

One expert in MM, with extensive experience with CAR T cells, confirmed that higher-grade toxicity tends to be associated with a higher tumor



[Blurred content area]



[Blurred content area]

Managing Toxicity of Bispecific Agents and CAR T Cells (2/2)

In terms of the financial impact of bispecific agents and CAR T cells,

A large, heavily blurred screenshot of a document or presentation slide, likely containing text and possibly a chart or table, but the content is illegible due to the blur effect.A large, heavily blurred screenshot of a document or presentation slide, similar to the one on the left, with illegible text and graphics.

CAR T Cells in Leukemias (1/2)

Expert opinion is that additional follow-up with CAR T cells in patients with acute lymphoblastic leukemia (ALL) is needed before CAR T cells can

[Blurred text area]





[Blurred text area]

CAR T Cells in Leukemias (2/2)

Expert opinion is that CAR T cells have activity against CNS disease

There is minimal enthusiasm for the potential of allogeneic CAR T

A large, heavily blurred screenshot of a document or presentation slide, likely containing text and possibly a diagram related to CAR T cell activity against CNS disease.A large, heavily blurred screenshot of a document or presentation slide, likely containing text and possibly a diagram related to the potential of allogeneic CAR T cells.

Bispecific Agents in Leukemias (1/2)

Expert recommendations for a patient with relapsed/refractory ALL would depend on whether a patient is being considered for stem cell



[Blurred text area containing expert recommendations for relapsed/refractory ALL treatment, including considerations for stem cell transplantation.]



[Blurred text area, likely containing additional clinical information or a list of agents.]



Bispecific Agents in Leukemias (2/2)

The experts are enthusiastic regarding combinations with

A large, blurred screenshot of a document or presentation slide, likely containing text and possibly a diagram or chart, but the content is illegible due to the blur effect.A smaller, blurred screenshot of a document or presentation slide, similar to the one on the left, with illegible text and a small blue circular graphic at the bottom right.

CAR T Cells in MM (1/2)



The experts discussed the likely approval of cilta-cel, resulting in 2 approved CAR T-cell therapies for patients with relapsed/refractory MM.

A blurred screenshot of a presentation slide. The slide contains several paragraphs of text, likely discussing the clinical trial results and regulatory status of cilta-cel. A prominent image of a red, oval-shaped pill is visible on the right side of the slide. The text is mostly illegible due to blurring.A blurred screenshot of a presentation slide, continuing the discussion from the previous slide. It contains several paragraphs of text, but the content is illegible due to blurring.

CAR T Cells in MM (2/2)



As with other diseases, the use of MRD assessment to tailor therapy

The experts think allogeneic CAR T cells have demonstrated a good



Bispecific Agents in Myeloma

Regarding the potential of bispecific agents in combination regimens in MM, one expert mentioned that quintuplets are being designed. However,



US Headquarters

5901-C Peachtree Dunwoody Road NE
Suite 200, Atlanta, GA 30328, US

EU Headquarters

Wilhelmina van Pruisenweg 104
2595 AN The Hague, the Netherlands

[apptitudehealth.com](https://www.apptitudehealth.com)

